Digital Content 
NEWS #PharmaBuzz
17 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/17/3063291/0/en/Actuate-to-Present-Promising-Data-on-Elraglusib-in-Advanced-Salivary-Gland-Carcinoma-at-the-AACR-Annual-Meeting-2025.html
25 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/25/3031941/0/en/Actuate-Announces-Completion-of-Enrollment-in-a-Phase-2-Trial-of-Elraglusib-in-Combination-with-FOLFIRINOX-and-Losartan-in-Patients-with-Previously-Untreated-Metastatic-Pancreatic-.html
07 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/07/3005368/0/en/Actuate-Therapeutics-Receives-EMA-Orphan-Medicinal-Product-Designation-for-Elraglusib-for-the-Treatment-of-Pancreatic-Cancer.html
17 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/17/2998254/0/en/Actuate-Therapeutics-Announces-Positive-Interim-Phase-2-Data-of-Elraglusib-in-First-Line-Treatment-of-Metastatic-Pancreatic-Cancer.html
12 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/12/2979076/0/en/Actuate-Announces-FDA-Rare-Pediatric-Disease-Designation-Granted-to-Elraglusib-for-Treatment-of-Ewing-Sarcoma.html
23 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/23/2951343/0/en/Actuate-Announces-Scientific-Reports-Publication-on-Elraglusib-s-Novel-Immunomodulatory-Mechanism-of-Action-as-a-GSK-3%CE%B2-Inhibitor.html
Share 